Who Paid My Doc
Karl Insogna
Endocrinology, Diabetes & Metabolism New Haven, CT Medical Doctor
NPI 1346223559 CMS profile 332615
789 Howard Ave, Dana Building - 3Rd Floor, New Haven, CT 06519
General payments
$67,944
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$834,719
Through program year 2025, Karl Insogna of New Haven, CT is reported in the CMS Open Payments database as having received $67,944 across 46 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $834,719 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 91st percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $12,066 | 12 | |
| 2024 | General | $14,974 | 18 | |
| 2023 | General | $2,811 | 4 | |
| 2022 | General | $5,671 | 2 | |
| 2019 | General | $32,423 | 10 |
Beside peers
- Karl Insogna
- Endocrinology, Diabetes & Metabolism median
- Middle half of Endocrinology, Diabetes & Metabolism
- National median
In program year 2025, general payments to Karl Insogna were reported at $12,066. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.
Show as a table
| Year | Karl Insogna | Endocrinology, Diabetes & Metabolism median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $32,423 | $494 | $123–$2,253 | $163 |
| 2020 | $0 | $335 | $85–$1,841 | $114 |
| 2021 | $0 | $398 | $88–$1,981 | $132 |
| 2022 | $5,671 | $364 | $88–$1,568 | $149 |
| 2023 | $2,811 | $420 | $113–$1,614 | $160 |
| 2024 | $14,974 | $440 | $121–$1,646 | $164 |
| 2025 | $12,066 | $507 | $135–$1,838 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
46 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Endocrinology, Diabetes & Metabolism in Connecticut
Practitioners in the same specialty and state, ranked by reported value.
All Endocrinology, Diabetes & Metabolism
Everyone recorded under this specialty, nationwide.
Doctors in Connecticut
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.